ArticleCirculation research2010
Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action.
Article in Circulation research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03930680 (Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane in Patients With Breast Cancer), which is not on this map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane in Patients With Breast Cancer
Who cites it
48 citing papers in PubMed, 87 citations in OpenAlex.
- TransEndocardial Injection of Autologous Expanded CD34Stem cell reviews and reports · 2026Trial
- Development of a potency assay for CD34Scientific reports · 2023Trial
- Industrialized GMP Production of CD34Stem cell reviews and reports · 2022Article
- Hypoimmune induced pluripotent stem cell-derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Transplantation of CD34+ cells for myocardial ischemia.World journal of transplantation · 2021Review
- Therapeutic Potential of Endothelial Colony-Forming Cells in Ischemic Disease: Strategies to Improve their Regenerative Efficacy.International journal of molecular sciences · 2020Review
- Key Success Factors for Regenerative Medicine in Acquired Heart Diseases.Stem cell reviews and reports · 2020Review
- Isolation Methods for Human CD34 Subsets Using Fluorescent and Magnetic Activated Cell Sorting: an In Vivo Comparative Study.Stem cell reviews and reports · 2020Article
- Exercise and Cardiovascular Progenitor Cells.Comprehensive Physiology · 2019Review
- Quantification and tracking of genetically engineered dendritic cells for studying immunotherapy.Magnetic resonance in medicine · 2018Article
- Cortical Bone Stem Cell Therapy Preserves Cardiac Structure and Function After Myocardial Infarction.Circulation research · 2017Article
- Thrombospondin-1-Derived Peptide RFYVVMWK Improves the Adhesive Phenotype of CD34Cell transplantation · 2017Article
- Metformin improves the angiogenic potential of human CD34⁺ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction.Cardiovascular diabetology · 2016Article
- Lysophosphatidic acid enhances survival of human CD34(+) cells in ischemic conditions.Scientific reports · 2015Article
- Chronic endurance exercise affects paracrine action of CD31+ and CD34+ cells on endothelial tube formation.American journal of physiology. Heart and circulatory physiology · 2015Article
- Mechanisms of bone marrow-derived cell therapy in ischemic cardiomyopathy with left ventricular assist device bridge to transplant.Journal of the American College of Cardiology · 2015Article
- Molecular imaging of stem cells for the treatment of acute myocardial infarction.International journal of clinical and experimental medicine · 2015Article
- The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy.Stem cells international · 2015Review
- Current Status and Perspectives in Stem Cell Therapy for Heart.Acta Cardiologica Sinica · 2014Review
- Efficiency of systemic versus intralesional bone marrow-derived stem cells in regeneration of oral mucosa after induction of formocresol induced ulcers in dogs.Dental research journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
rationaleHuman CD34(+) cells have been used in clinical trials for treatment of myocardial infarction (MI). However, it is unknown how long the CD34(+) cells persist in hearts, whether the improvement in cardiac function is sustained, or what are the underlying mechanisms.
objectiveWe sought to track the fate of injected human CD34(+) cells in the hearts of severe combined immune deficiency (SCID) mice after experimental MI and to determine the mechanisms of action. METHODS AND
resultsWe used multimodality molecular imaging to track the fate of injected human CD34(+) cells in the hearts of SCID mice after experimental MI, and used selective antibody blocking to determine the mechanisms of action. Bioluminescence imaging showed that injected CD34(+) cells survived in the hearts for longer than 12 months. The PET signal from the injected cells was detected in the wall of the left ventricle. Cardiac MRI showed that left ventricular ejection fraction was significantly improved in the treated mice compared to the control mice for up to 52 weeks (P<0.05). Furthermore, treatment with anti-alpha4beta1 showed that generation of human-derived cardiomyocytes was inhibited, whereas anti-vascular endothelial growth factor (VEGF) treatment blocked the production of human-derived endothelial cells. However, the improvement in cardiac function was abolished only in the anti-VEGF, but not anti-alpha4beta1, treated group.
conclusionsAngiogenesis and/or paracrine effect, but not myogenesis, is responsible for functional improvement following CD34(+) cells therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.